| Pharmaceutical Information |
| Drug Name |
Zalcitabine |
| Drug ID |
BADD_D02378 |
| Description |
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. |
| Indications and Usage |
For the treatment of Human immunovirus (HIV) infections in conjunction with other antivirals. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AF03 |
| DrugBank ID |
DB00943
|
| KEGG ID |
D00412
|
| MeSH ID |
D016047
|
| PubChem ID |
24066
|
| TTD Drug ID |
D0Z9QR
|
| NDC Product Code |
Not Available |
| UNII |
6L3XT8CB3I
|
| Synonyms |
Zalcitabine | Dideoxycytidine | 2',3'-Dideoxycytidine | 2',3' Dideoxycytidine | ddC (Antiviral) | NSC-606170 | NSC 606170 | NSC606170 | Hivid | HIVID Roche |
|
| Chemical Information |
| Molecular Formula |
C9H13N3O3 |
| CAS Registry Number |
7481-89-2 |
| SMILES |
C1CC(OC1CO)N2C=CC(=NC2=O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
